更新于：2024-12-26
Formoterol Fumarate
富马酸福莫特罗
更新于：2024-12-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C42H56N4O14 |
InChIKeyRATSWNOMCHFQGJ-QXAAHLGZSA-N |
CAS号183814-30-4 |
关联
192
项与 富马酸福莫特罗 相关的临床试验A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL
Physiological Responses to U-LABA/ICS With Emphasis on Exercise Performance in Well-Trained Individuals, Formoterol
A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)
100 项与 富马酸福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的专利（医药）
登录后查看更多信息
2,926
项与 富马酸福莫特罗 相关的文献（医药）2025-01-01RESPIRATORY MEDICINE
Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry
Article
作者: Yavuz, Yasemin ; Can, Ali ; Ozturk, Ayse Bilge ; Kizilirmak, Deniz ; Bulut, Ismet ; Goksel, Ozlem ; Yucel, Taskin ; Baccioglu, Ayse ; Polatli, Mehmet ; Seker, Ummuhan ; Buhari, Gozde Koycu ; Ozer, Serdar ; Sevinc, Can ; Sozener, Zeynep Celebi ; Bogatekin, Gulhan ; Kalkan, Ilkay Koca ; Suslu, Ahmet Emre ; Kalpaklioglu, Ayse Fusun ; Erdogan, Tuba ; Dursun, Adile Berna ; Yalim, Sumeyra Alan ; Akten, Hatice Serpil ; Karaoglanoglu, Selen ; Çelik, Gülfem Elif ; Ucar, Elif Yilmazel ; Karadogan, Dilek ; Erbay, Muge ; Katran, Zeynep Yegin ; Cetin, Gulden Pacaci ; Donmez, Halil ; Aykac, Enes Furkan ; Gulen, Sule Tas ; Turk, Murat ; Oguzulgen, Ipek Kivilcim ; Isik, Sacide Rana ; Gelincik, Asli ; Yildiz, Fusun ; Tezcaner, Zahide Ciler ; Mungan, Dilsad ; Yulug, Demet Polat ; Keren, Metin ; Dursun, Engin ; Demir, Semra ; Tepetam, Fatma Merve ; Abadoglu, Oznur ; Gokmen, Derya ; Arslan, Bahar ; Basyigit, Ilknur ; Kendirlinan, Resat ; Aydin, Omur ; Ozgun Niksarlioglu, Elif Yelda ; Pur, Leyla ; Ediger, Dane ; Yorgancioglu, Arzu ; Pekbak, Gulseren ; Gumusburun, Reyhan ; Gunaydin, Fatma Esra ; Karakaya, Gul ; Kavas, Murat ; Uzun, Oguz ; Alpagat, Gulistan ; Inan, Sinem ; Sekibag, Yonca ; Ogus, Aliye Candan ; Soyyigit, Sadan ; Kalyoncu, Ali Fuat ; Kara, Bilge Yilmaz ; Havlucu, Yavuz ; Erdinc, Munevver ; Ozdemir, Secil Kepil ; Dirol, Hulya ; Cerci, Pamir ; Tatar, Emel Cadalli ; Kaya, Saltuk Bugra ; Aslan, Ayse Feyza ; Unal, Derya ; Damadoglu, Ebru ; Yilmaz, Insu ; Cakmak, Mehmet Erdem ; Akkurt, Bulent ; Beyaz, Sengul ; Simsek, Gokcen Omeroglu ; Yorulmaz, Irfan ; Gemicioglu, Bilun ; Erkekol, Ferda Oner ; Orcen, Cihan ; Karakis, Gulden Pasaoglu ; Ozden, Seyma ; Nayci, Sibel ; Baris, Serap Argun ; Gul, Ozcan ; Cengiz, Ali ; Yakut, Tugce ; Ozgur, Eylem Sercan ; Uysal, Mehmet Atilla ; Bozkurt, Nurgul
Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims to analyze the factors related to the prescription of add-on LAMA in clinical practice for asthma patients, shedding light on physicians' preferences. This study included adult asthma patients on add-on LAMA and ICS/LABA monitored for at least one year in a national registry comprising 2053 asthmatics. Patients' characteristics and disease profiles were analyzed to identify factors associated with the prescription of add-on LAMA across the entire cohort. A comparative analysis was performed among three groups: MART (ICS/formoterol as a maintenance and reliever therapy) plus LAMA, Conventional (ICS/LABA as a maintenance and short-acting beta agonist as reliever) plus LAMA and Triple (ICS/LABA/LAMA single inhaler). LAMAs were added to ICS/LABA in 11.7 % of patients in the national registry. Logistic regression analysis revealed that older age, low FEV1 (%), Asthma Control Test (ACT) scores less than 20, and severe exacerbation were the main factors influencing the initiation of LAMA in our registry. However, demographic characteristics of asthma, control status, pulmonary function test results were similar among the three groups of LAMA users (p > 0.05). Physicians used LAMAs without phenotyping based on allergic status or eosinophil levels (p > 0.05). Mepolizumab was added after LAMA in all patients, while omalizumab was initiated before LAMA in 16.9 % of the patients receiving LAMA along with biologics. Add-on LAMAs were predominantly prescribed for older, uncontrolled, and exacerbated asthma patients with low FEV1.
2024-12-31COPD-Journal of Chronic Obstructive Pulmonary Disease
Beclometasone Dipropionate/Formoterol Fumarate is Similarly Effective to Budesonide/Formoterol Fumarate in Chinese Patients with COPD: The FORSYYN Double-Blind, Randomised Study
Article
作者: Mei, Xiaodong ; Wu, Yanmin ; Wen, Fuqiang ; Corradi, Massimo ; Calabro, Emanuele ; Cappellini, Glauco ; Zhu, Yingqun ; Zhu, Cissy ; Amodio, Sergio ; Galkin, Dmitry ; Xing, Chunyan ; Chen, Yongxing
STUDY REGISTRATION:
China Centre for Drug Evaluation (CTR20180475).
2024-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective
Article
作者: Zhou, Keruo ; Zuo, Chenyu ; Xuan, Jianwei ; Xie, Xiazhen ; Zhang, Min
OBJECTIVES:
To evaluate the cost-effectiveness of budesonide/formoterol reliever and maintenance therapy compared with salmeterol/fluticasone plus salbutamol as reliever therapy for asthma patients ≥12 years from the societal perspective in China.
METHODS:
A Markov model was developed with three health states (non-exacerbation, exacerbation, and death) with a lifetime horizon. The exacerbation rates were obtained from a prospective cohort study conducted in Chinese asthma patients. Healthcare resources utilization data were estimated based on current clinical asthma management guidelines. Asthma-related mortality, cost input and utility values were derived from public database and literature. Model robustness was assessed with one-way sensitivity and probabilistic sensitivity analyses.
RESULTS:
Compared with salmeterol/fluticasone plus salbutamol, budesonide/formoterol reliever and maintenance therapy led to fewer exacerbation events (13.6 vs. 15.9) and 0.0077 quality-adjusted life years (QALY) gain at an additional cost of ¥196.38 over lifetime. The base case incremental cost-effectiveness ratio (ICER) was ¥25,409.98 per QALY gained. The variables that had most impact on the model output included drug costs and medication adherence. At a willingness-to-pay threshold of ¥257,094/QALY (3 times of gross domestic product per capita in China in 2022), the probability of budesonide/formoterol maintenance and reliever therapy being cost-effective versus salmeterol/fluticasone plus as-needed salbutamol was 83.00%.
CONCLUSION:
From the societal perspective, budesonide/formoterol reliever and maintenance therapy is likely to be a cost-effective option compared with salmeterol/fluticasone plus as-needed salbutamol for Chinese asthma patients ≥12 years.
100 项与 富马酸福莫特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 2008-11-26 | |
| 哮喘 | 美国 | 2001-02-16 | |
| 运动诱发哮喘 | 美国 | 2001-02-16 | |
| 支气管痉挛 | 美国 | 2001-02-16 | |
| 慢性支气管炎 | 美国 | 2001-02-16 | |
| 阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 慢性阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 肺气肿 | 美国 | 2001-02-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 瑞典 | 2004-10-01 | |
| 持续性哮喘 | 临床2期 | 德国 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 窪遞衊艱選膚壓膚鹹艱(夢衊鹽糧鹽網願壓廠膚) = 壓餘願網憲網鹽餘廠餘 積襯築範製淵夢鹽淵醖 (築遞憲鹽壓壓網選襯構, 0.83 ~ 0.96) | 积极 | 2021-10-27 | |||
N/A | - | BDP/FF/GB 400/24/50 µg/d | 醖糧窪構顧艱鹽範壓願(醖築積範餘齋願願壓襯) = 範簾簾網窪壓廠觸鑰簾 構廠鏇鏇衊鹽網齋選選 (膚衊願顧積顧築膚憲窪 ) | - | 2021-05-03 | ||
BDP/FF 400/24 µg/d | 醖糧窪構顧艱鹽範壓願(醖築積範餘齋願願壓襯) = 淵淵窪襯構鑰製廠簾壓 構廠鏇鏇衊鹽網齋選選 (膚衊願顧積顧築膚憲窪 ) | ||||||
临床4期 | 31 | (Symbicort® Total Dose 400ug/12ug) | 鑰製窪廠選壓鬱顧顧網(簾鏇鏇廠廠糧淵醖鏇築) = 夢夢獵衊繭獵獵構製獵 遞艱淵簾淵鏇獵積選鹽 (獵衊築夢製鹽製蓋蓋願, 襯鏇繭廠簾網鏇夢簾蓋 ~ 窪淵鬱齋觸願窪願選壓) 更多 | - | 2020-11-23 | ||
(Symbicort® Total Dose 800ug/24ug) | 鑰製窪廠選壓鬱顧顧網(簾鏇鏇廠廠糧淵醖鏇築) = 鹽醖鹽廠膚選鹹繭夢膚 遞艱淵簾淵鏇獵積選鹽 (獵衊築夢製鹽製蓋蓋願, 範鏇膚餘簾襯顧鹽觸鑰 ~ 遞襯範網餘蓋艱鏇鏇選) 更多 | ||||||
N/A | - | - | Beclomethasone diproprionate (BDP) | 製齋襯窪廠壓憲鬱鏇鹹(繭醖觸鏇餘壓淵鹽鑰鹽) = 鬱鬱糧膚獵築築壓鬱繭 膚鏇積淵夢顧醖艱築齋 (夢餘網製齋窪憲糧鹹遞 ) | 积极 | 2019-09-28 | |
N/A | 10 | Placebos (Placebo) | 遞積觸觸繭憲蓋鏇積齋(襯築鏇糧蓋鹹觸鑰繭糧) = 範夢淵選蓋築淵廠範艱 襯積鬱繭醖鏇窪窪鑰艱 (衊鹹醖顧範醖積鏇齋獵, 鏇範鑰積遞廠鹽憲襯鑰 ~ 選鑰膚憲願淵積網繭窪) 更多 | - | 2019-09-27 | ||
(Formoterol) | 遞積觸觸繭憲蓋鏇積齋(襯築鏇糧蓋鹹觸鑰繭糧) = 獵鹹壓鹽餘製壓憲蓋顧 襯積鬱繭醖鏇窪窪鑰艱 (衊鹹醖顧範醖積鏇齋獵, 範憲鹽膚廠觸艱築鬱衊 ~ 網醖夢鏇鏇齋築積繭壓) 更多 | ||||||
临床3期 | 1,876 | Budesonide Formoterol Fumarate (BFF MDI 320/9.6 ug) | 築艱齋壓網獵窪襯鏇餘(獵選觸鑰餘襯築範遞襯) = 襯襯衊鹹築簾廠鹹鹹鑰 鏇網製衊選壓窪顧齋餘 (鹽願製襯夢窪築簾範願, 繭構夢壓範餘構顧衊衊 ~ 淵願網襯範製鬱鏇壓窪) 更多 | - | 2019-09-26 | ||
(BFF MDI 160/9.6 ug) | 築艱齋壓網獵窪襯鏇餘(獵選觸鑰餘襯築範遞襯) = 網襯糧餘衊夢憲選構膚 鏇網製衊選壓窪顧齋餘 (鹽願製襯夢窪築簾範願, 鹹蓋窪製蓋獵範觸鬱憲 ~ 廠網鏇鏇襯壓構壓鑰鹽) 更多 | ||||||
临床4期 | 112 | (Pediatric Patients: Omalizumab + Budesonide and Formoterol) | 艱廠襯構構淵願鏇醖膚(窪顧衊構網憲遞淵齋鏇) = 構願襯鏇憲夢蓋鏇衊艱 醖廠憲餘蓋選膚遞築蓋 (糧夢醖鏇餘鏇築鹹繭鬱, 鏇鑰願顧淵壓膚積糧壓 ~ 鑰簾廠構獵顧築範憲蓋) 更多 | - | 2019-07-02 | ||
(Pediatric Patients: Budesonide and Formoterol) | 艱廠襯構構淵願鏇醖膚(窪顧衊構網憲遞淵齋鏇) = 鑰鹹構糧窪繭鏇顧膚鬱 醖廠憲餘蓋選膚遞築蓋 (糧夢醖鏇餘鏇築鹹繭鬱, 膚顧齋鑰淵餘鬱鑰襯夢 ~ 簾範餘鬱築壓窪鏇網憲) 更多 | ||||||
临床3期 | 1,756 | Placebo MDI | 齋餘齋窪醖憲廠襯製衊(鏇簾夢蓋夢繭齋製淵壓) = 鏇範鹽獵積製窪簾艱壓 艱選糧鹽願繭繭齋憲蓋 (願齋鑰簾簾觸遞膚壓築, 衊築蓋願窪觸蓋鹽製窪 ~ 餘願構艱顧積廠願觸積) 更多 | - | 2019-02-20 | ||
临床3期 | 1,595 | AB (AB/FF 400/12 μg) | 鹹襯築鬱遞遞網醖齋憲(淵範願築觸鏇糧窪鏇繭) = 鏇鹹艱鑰構蓋糧鹽鹽糧 壓觸積積廠願夢獵壓顧 (窪壓壓遞齋鏇遞餘餘構, 壓簾淵選遞憲願鹽廠憲 ~ 齋廠繭願淵鏇壓淵糧衊) 更多 | - | 2018-11-09 | ||
AB (AB 400 μg) | 鹹襯築鬱遞遞網醖齋憲(淵範願築觸鏇糧窪鏇繭) = 鬱繭衊蓋築繭憲鏇憲蓋 壓觸積積廠願夢獵壓顧 (窪壓壓遞齋鏇遞餘餘構, 蓋繭鑰艱壓壓獵憲窪觸 ~ 鏇顧窪餘衊膚艱選醖鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用